Ferric carboxymaltose

Hospital Pharmacy

Volumn 49, Issue 1, 2014, Pages 52-69

  Cada, Dennis ^a   Levien, Terri ^b   Baker, Danial ^b  

^a Wolters Kluwer Health   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BAZEDOXIFENE; BENZYL ALCOHOL; CONJUGATED ESTROGEN; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERUMOXYTOL; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; IRON; IRON DEXTRAN; IRON SACCHARATE; MACITENTAN; OBINUTUZUMAB; RIOCIGUAT; TRANSFERRIN;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; BREAST FEEDING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULARY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFORMATION; DRUG MONITORING; DRUG SAFETY; DYSGEUSIA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GERIATRIC PATIENT; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION SITE DISCOLORATION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; KIDNEY DISEASE; LIMIT OF QUANTITATION; LIVER DISEASE; MOLECULAR WEIGHT; NAUSEA; NOSE DISEASE; PARESTHESIA; PATIENT MONITORING; PRACTICE GUIDELINE; PREGNANT WOMAN; RASH; REVIEW; RISK ASSESSMENT; SCIENTIFIC LITERATURE; SNEEZING; TREATMENT FAILURE; VOMITING;

EID: 84892172894     PISSN: 00185787     EISSN: 19451253     Source Type: Journal    
DOI: 10.1310/hpj4901-52     Document Type: Review

References (36)

1. Injectafer [package insert]. Shirley, NJ: American Regent Inc; July 2013.
2. Bailie GR, Mason NA, Valaoras TG. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Hemodial Int. 2010;14(1):47-54.
3. Geisser P, Banké-Bochita J. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: A doseescalation study in volunteers with mild iron-deficiency anaemia. Arzneimittelforschung. 2010;60(6a):362-372.
4. Geisser P, Rumyantsev V. Pharmacodynamics and safety of ferric carboxymaltose: A multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder. Arzneimittelforschung. 2010;60(6a):373-385.
5. Medicines and Healthcare Products Regulatory Agency. Public Assessment Report Mutual Recognition Procedure: Ferinject 50 mg iron/ml solution for injection/infusion (ferric carboxymaltose). http://www.mhra.gov.uk/home/groups/ l-unit1/documents/websiteresources/con014025.pdf. Accessed February 8, 2012.
6. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4): 279-335.
7. KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease [published correction appears in Am J Kidney Dis. 2006;48(3):518]. Am J KidneyDis. 2006;47(5) (suppl 3):S11-S145. http://www.kidney.org/professionals/ KDOQI/guidelines-anemia/cpr32.htm. Accessed April 15, 2013.
8. Szczech LA, Bregman DB, Morris DD, et al. Direct comparison of ferric carboxymaltose vs. Venofer in 2500 patients with iron deficiency anemia and impaired renal function (REPAIR-IDA) [abstract]. J Am Soc Nephrol. 2011; 22:5B.
9. Szczech LA, Bregman DB,Harrington RA, et al. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patientswith iron deficiency anaemia and impaired renal function (REPAIR-IDA): Rationale and study design. Nephrol Dial Transplant. 2010;25(7):2368-2375.
10. Schaefer RM, Khasabov NN, Todorov NG, et al. The efficacy and safety of intravenous ferric carboxymaltose compared to iron sucrose in haemodialysis patients with iron deficiency anemia [abstract]. Nephrol Dial Transplant Plus. 2008;1(suppl 1):ii360.
11. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltosewith oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26(5):1599-1607.
12. Charytan C, Bernardo MV, Koch TA, Butcher A, Morris D, Bregman DB. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: A randomized, activecontrolled, multicenter study. Nephrol Dial Transplant. 2013;28(4):953-964.
13. Covic A, Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: A multi-centre, open-label, clinical study. Nephrol Dial Transplant. 2010;25(8):2722-2730.
14. Tagboto S, Cropper L, Turner J, Pugh-Clarke K. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients. J Renal Care. 2009;35(1):18-23.
15. Grimmelt AC, Cohen CD, Fehr T, Serra AL, Wuethrich RP. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol. 2009; 71(2):125-129.
16. Goddard AF, James MW, McIntyre AS, Scott BB; British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia. Gut. 2011;60(10):1309-1316.
17. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 95: Anemia in pregnancy. Obstet Gynecol. 2008;112(1):201-207.
18. Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia [published online ahead of print June 17, 2013]. Transfusion. doi: 10.1111/trf.12289
19. Barish CF, Koch T, Butcher A, Morris D, Bregman DB. Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: Two randomized, controlled trials [published online ahead of print September 10, 2012]. Anemia. doi: 10.1155/2012/172104
20. Christoph P, Schuller C, Studer H, Irion O, De Tejada BM, Surbek D. Intravenous iron treatment in pregnancy: Comparison of high-dose ferric carboxymaltose vs. iron sucrose. J Perinat Med. 2012;40(5):469-474.
21. Pfenniger A, Schuller C, Christoph P, Surbek D. Safety and efficacy of high-dose intravenous iron carboxymaltose vs. iron sucrose for treatment of postpartum anemia. J Perinat Med. 2012;40(4):397-402.
22. Evstatiev R, Marteau P, Iqbal T, et al; FERGI Study Group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141(3):846-853.
23. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: A randomized, controlled trial. Transfusion. 2009;49 (12):2719-2728.
24. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: A randomized controlled clinical trial. Am JObstet Gynecol. 2008;199(4);435. e1-e7.
25. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: A randomized controlled trial [published correction appears in Obstet Gynecol. 2008;111(4):996]. Obstet Gynecol. 2007;110(2, pt 1):267-278.
26. Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008;101(1):67-73.
27. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103(5): 1182-1192.
28. Bisbe E, García-Erce JA,Díez-Lobo AI,Munoz M; Anaemia Working Group Espana. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Br J Anaesth. 2011;107(3): 477-478.
29. Dillon R, Momoh I, Francis Y, Cameron L, Harrison CN, Radia D. Comparative efficacy of three forms of parenteral iron. J Blood Transfusion. 2012;2012. doi: 10.1155/2012/473514
30. Feraheme [package insert]. Lexington, MA: AMAG Pharmaceuticals Inc; November 2011.
31. Dexferrum [package insert]. Shirley, NY: American Regent Inc; August 2008.
32. INFeD [package insert]. Morristown, NJ: Watson Pharma Inc; September 2009.
33. Venofer [package insert]. Waltham, MA: Fresenius Medical Care NA; October 2012.
34. Ferrlecit [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC; August 2011.
35. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011;3(1): 12-33.
36. Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program. 2010;2010:338-347.